<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01743755</url>
  </required_header>
  <id_info>
    <org_study_id>Santeon-CAP</org_study_id>
    <secondary_id>2011-004566-14</secondary_id>
    <nct_id>NCT01743755</nct_id>
  </id_info>
  <brief_title>Santeon-CAP; Dexamethasone in Community-acquired Pneumonia</brief_title>
  <official_title>Santeon-CAP; Dexamethasone in Community-acquired Pneumonia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Antonius Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canisius-Wilhelmina Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Onze Lieve Vrouw Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Catharina Ziekenhuis Eindhoven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maasstad Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Antonius Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study is designed to investigate the beneficial effects of adjunctive
      dexamethasone therapy in patients admitted with community-acquired pneumonia, additionally
      aiming at assessing what patients benefit from dexamethasone treatment mostly. A large
      multicenter study will be conducted comparing a 4 days dexamethasone 6 mg per os course with
      placebo in 600 patients and with predefined subgroup analyses planned.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Community-acquired pneumonia (CAP) is a common infection. Approximately 20 percent of all
      episodes of pneumonia result in hospitalization. It is the leading cause of
      community-acquired infection requiring intensive care unit (ICU) admission. In pulmonary
      infections, the release of cytokines and other inflammatory mediators from alveolar
      macrophages serves as a mechanism by which invading pathogens are eliminated. However, this
      reaction of the innate immune system can be potentially harmful when excessive release of
      circulating inflammatory cytokines causes damage to the patient, particularly the lung.
      Interest in the role of corticosteroids in the pathophysiology of critical illness has
      existed since the early part of the 20th century. On ICU, early treatment with
      corticosteroids to attenuate systemic inflammation is widespread. At the same time, outside
      the ICU little evidence is available on the effect of treatment with corticosteroids in
      patients diagnosed with CAP. Theoretically, early initiated administration of corticosteroids
      in the course of a CAP can lower systemic and pulmonary inflammation. This may lead to
      earlier resolution of pneumonia and a reduction of complications (sepsis, mortality).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>Hospital admission (= day 1 = timepoint at which patient presents in hospital) until hospital discharge; participants will be followed for the duration of hospital stay, an expected average of 1 week.</time_frame>
    <description>Discharge date will be the date on which the patient is clinically ready to be discharged (which means days of hospital stay on basis of social indication will be excluded from analyses). Median length of stay in an earlier CAP study performed in the St. Antonius Hospital in Nieuwegein was 6.5 days, thus patients will be followed during an expected average of 1 week.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>day 30</time_frame>
    <description>30 days after hospital admission (=day 1) the patient will visit the hospital for a out-patient visit. At that time, patient's status will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU admission</measure>
    <time_frame>hospital admission (=day 1) until hospital discharge; participants will be followed for the duration of hospital stay, an expected average of 1 week.</time_frame>
    <description>In the period the patient is admitted to the hospital, admission to the intensive care unit will be recorded (yes/no and specific date).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Mortality</measure>
    <time_frame>Day 365</time_frame>
    <description>One year after admission patient's status will be recorded.</description>
  </other_outcome>
  <other_outcome>
    <measure>S. pneumoniae prevalence</measure>
    <time_frame>Hospital admission (= day 1)</time_frame>
    <description>To study the prevalence of different S. pneumoniae serotypes in The Netherlands (based on the serotype distribution of isolated strains as well as the increase of serotype specific antibodies). Serotyping will be performed in a bloodsample taken on the day of admission.</description>
  </other_outcome>
  <other_outcome>
    <measure>Renal damage</measure>
    <time_frame>Admission (=day 1) and day 30 (outpatient visist)</time_frame>
    <description>To study acute renal damage, and its effect on outcome, in patients with CAP. A urine sample will be taken on the day of admission, on day 4 and on the outpatient visit at day 30.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cost-effectiveness</measure>
    <time_frame>Hospital discharge; participants will be followed for the duration of hospital stay, an expected average of 1 week.</time_frame>
    <description>To study the cost-effectiveness of dexamethasone and outcome of CAP. Resource utilization will be acquired for the entire period of hospital stay for each individual patient.</description>
  </other_outcome>
  <other_outcome>
    <measure>Post-infectious fatigue</measure>
    <time_frame>Day 30 and day 90</time_frame>
    <description>To study post-infectious fatigue that occurs in certain patients after a CAP episode. On day 1, day 4, day of discharge, and 30 and 90 days after admission, the patient will be asked to fill in the EQ-5D questionnaire. Furthermore, on day 4, 30 and 90 days after admission, the patient will be asked to fill in the RAND-36 questionnaire.</description>
  </other_outcome>
  <other_outcome>
    <measure>Pathogenesis of CAP at respiratory mucosa</measure>
    <time_frame>Day of admission (=day 1) and day 30 (outpatient visit)</time_frame>
    <description>To study the pathogenesis of CAP at the respiratory mucosa (this will be done in two of the four study centra). At the day of hospital admission a nasopharyngeal swab will be taken to determine aetiology of the respiratory mucose. 30 days after admission (during the outpatient visit) another nasopharyngeal swab will be taken to explore changes.</description>
  </other_outcome>
  <other_outcome>
    <measure>Predefined subgroup analysis of length of stay</measure>
    <time_frame>Hospital discharge; participants will be followed for the duration of hospital stay, an expected average of 1 week.</time_frame>
    <description>To study what patients admitted with CAP benefit most from dexamethasone therapy, based on predefined subgroup analysis with:
disease severity score (PSI 1-3 vs. PSI 4-5);
C-reactive protein level at admission;
causative microorganism (Pneumococcus urinary antigen test positive vs. negative);
cytokine response (IL-6 and IL-10) over time;
cortisol level over time;
procalcitonin over time;
vitamin D level on admission.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Community-acquired Pneumonia</condition>
  <arm_group>
    <arm_group_label>Dexamethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet, once daily for four consecutive days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone tablet 6 mg, once daily for four consecutive days</description>
    <arm_group_label>Dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet, once daily for four consecutive days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years or older

          -  Chest radiograph showing new opacities.

        In combination with two of the following findings:

          -  Cough

          -  Production of sputum

          -  Temp &gt;38,0 °C or &lt;36,0 °C

          -  Audible abnormalities by chest examination compatible with pneumonia

          -  Leukocytosis (&gt;10.000 cells/mm3), leftward shift (&gt;10%) or leucopenia (&lt;4000
             cells/mm3)

          -  C-reactive protein &gt; 15 mg/l (three fold higher than the upper limit of normal)

        Exclusion Criteria:

          -  Immunocompromised patients:

          -  Patients with a known congenital or acquired immunodeficiency.

          -  Patients who received chemotherapy less than 6 weeks ago.

          -  Patients who received corticosteroids in the last 6 weeks.

          -  Patients who received immunosuppressive medication in the last 6 weeks (e.g.
             cyclosporin, cyclophosphamide, azathioprine).

          -  Patients with chronic obstructive pulmonary disease who are on systemic
             corticosteroids.

          -  Patients who require intensive care unit treatment.

          -  Patients with tropical worm infection.

          -  Patients with dexamethasone intolerance.

          -  Pregnant and breastfeeding women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Willem Jan Bos, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Antonius Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jan Grutters, Prof, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Antonius Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rob Janssen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Canisius-Wilhelmina Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frank Smeenk, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Catharina Ziekenhuis Eindhoven</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul Bresser, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Onze Lieve Vrouwen Gasthuis</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stijn Konings, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Catharina Ziekenhuis Eindhoven</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Willem Blok, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Onze Lieve Vrouwen Gasthuis</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stefan Vestjens, MD</last_name>
    <email>s.vestjens@antoniusziekenhuis.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Simone Spoorenberg, MD</last_name>
    <email>s.spoorenberg@antoniusziekenhuis.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Canisius Wilhelmina Hospital</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <zip>6532 SZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rob Janssen, MD</last_name>
    </contact>
    <investigator>
      <last_name>Rob Janssen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hester Zeegers, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tom Sprong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Catharina hospital Eindhoven</name>
      <address>
        <city>Eindhoven</city>
        <state>Noord-Brabant</state>
        <zip>5623 EJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Smeenk, MD</last_name>
    </contact>
    <investigator>
      <last_name>Frank Smeenk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stijn Konings, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OLVG</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1091 AC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Bresser, MD</last_name>
    </contact>
    <investigator>
      <last_name>Paul Bresser, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Willem Blok, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Antonius Hospital</name>
      <address>
        <city>Nieuwegein</city>
        <state>Utrecht</state>
        <zip>3430 EM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Vestjens, MD</last_name>
      <phone>0031613851127</phone>
      <email>s.vestjens@antoniusziekenhuis.nl</email>
    </contact>
    <contact_backup>
      <last_name>Willem Jan Bos, MD</last_name>
      <phone>0031652741245</phone>
      <email>w.bos@antoniusziekenhuis.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Stefan Vestjens, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Simone Spoorenberg, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Willem Jan Bos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jan Grutters, MD, prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Meijvis SC, Hardeman H, Remmelts HH, Heijligenberg R, Rijkers GT, van Velzen-Blad H, Voorn GP, van de Garde EM, Endeman H, Grutters JC, Bos WJ, Biesma DH. Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial. Lancet. 2011 Jun 11;377(9782):2023-30. doi: 10.1016/S0140-6736(11)60607-7. Epub 2011 Jun 1.</citation>
    <PMID>21636122</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 22, 2012</study_first_submitted>
  <study_first_submitted_qc>December 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2012</study_first_posted>
  <last_update_submitted>April 20, 2018</last_update_submitted>
  <last_update_submitted_qc>April 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. Antonius Hospital</investigator_affiliation>
    <investigator_full_name>Dr. WJW Bos</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Community-acquired pneumonia</keyword>
  <keyword>Dexamethasone</keyword>
  <keyword>Corticosteroid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

